Telix Pharmaceuticals 관리

관리 기준 확인 4/4

Telix Pharmaceuticals' CEO is Chris Behrenbruch, appointed in Jul 2023, has a tenure of 1.33 years. total yearly compensation is A$1.02M, comprised of 49% salary and 51% bonuses, including company stock and options. directly owns 6.97% of the company’s shares, worth $328.03M. The average tenure of the management team and the board of directors is 2.2 years and 7.2 years respectively.

주요 정보

Chris Behrenbruch

최고 경영자

AU$1.0m

총 보상

CEO 급여 비율	49.0%
CEO 임기	1.3yrs
CEO 소유권	7.0%
경영진 평균 재임 기간	2.2yrs
이사회 평균 재임 기간	7.2yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Chris Behrenbruch 의 보수는 Telix Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	AU$49m
Mar 31 2024	n/a	n/a	AU$32m
Dec 31 2023	AU$1m	AU$499k	AU$5m
Sep 30 2023	n/a	n/a	-AU$21m
Jun 30 2023	n/a	n/a	-AU$48m
Mar 31 2023	n/a	n/a	-AU$77m
Dec 31 2022	AU$865k	AU$422k	-AU$104m
Sep 30 2022	n/a	n/a	-AU$111m
Jun 30 2022	n/a	n/a	-AU$119m
Mar 31 2022	n/a	n/a	-AU$100m
Dec 31 2021	AU$620k	AU$374k	-AU$81m
Sep 30 2021	n/a	n/a	-AU$70m
Jun 30 2021	n/a	n/a	-AU$59m
Mar 31 2021	n/a	n/a	-AU$52m
Dec 31 2020	AU$421k	AU$295k	-AU$45m
Sep 30 2020	n/a	n/a	-AU$40m
Jun 30 2020	n/a	n/a	-AU$36m
Mar 31 2020	n/a	n/a	-AU$32m
Dec 31 2019	AU$460k	AU$317k	-AU$28m
Sep 30 2019	n/a	n/a	-AU$23m
Jun 30 2019	n/a	n/a	-AU$19m
Mar 31 2019	n/a	n/a	-AU$16m
Dec 31 2018	AU$380k	AU$280k	-AU$14m
Sep 30 2018	n/a	n/a	-AU$12m
Jun 30 2018	n/a	n/a	-AU$10m
Mar 31 2018	n/a	n/a	-AU$8m
Dec 31 2017	AU$303k	AU$211k	-AU$6m

보상 대 시장: Chris's total compensation ($USD667.62K) is below average for companies of similar size in the US market ($USD6.66M).

보상과 수익: Chris's compensation has been consistent with company performance over the past year.

CEO

Chris Behrenbruch (48 yo)

1.3yrs

테뉴어

AU$1,018,461

보상

Dr. Christian P. Behrenbruch, also known as Chris, BEng (Hons), J.D., Ph.D. DPhil (Oxon), MBA (TRIUM), JD (Melb), FIEAust, GAICD, is Co-Founder, Chief Executive Officer and Managing Director of Telix Pharm...

리더십 팀

이름	위치	테뉴어	보상	소유권
Christian Behrenbruch	Co-Founder	1.3yrs	AU$1.02m	6.97% $ 328.0m
Darren Smith	Group Chief Financial Officer	2.3yrs	AU$713.90k	0.0019% $ 91.3k
Andreas Kluge	Chief Medical Advisor	no data	AU$43.00k	6.78% $ 318.8m
David Cade	Group Chief Medical Officer	less than a year	데이터 없음	0.11% $ 5.2m
Richard Valeix	Chief Executive Officer of Telix Therapeutics	3.5yrs	AU$902.90k	0.060% $ 2.8m
Darren Patti	Group Chief Operating Officer	less than a year	데이터 없음	0.030% $ 1.4m
Michael Wheatcroft	Chief Scientist	3.5yrs	AU$167.76k	데이터 없음
Craig Ulrick	Chief Information Officer	1.8yrs	데이터 없음	데이터 없음
Kyahn Williamson	Senior Vice President of Corporate Communications & Investor Relations	3.3yrs	데이터 없음	데이터 없음
Lena Moran-Adams	Group General Counsel	2.2yrs	데이터 없음	데이터 없음
Thomas Fromm	Vice President of Sales	no data	데이터 없음	데이터 없음
Meredith Crowe	Senior Vice President of Global People & Culture	2.2yrs	데이터 없음	데이터 없음

2.2yrs

평균 재임 기간

53.5yo

평균 연령

경험이 풍부한 관리: TLPP.F's management team is considered experienced (2.2 years average tenure).

이사회 구성원

이름	위치	테뉴어	보상	소유권
Christian Behrenbruch	Co-Founder	7.8yrs	AU$1.02m	6.97% $ 328.0m
Harry McCann	Independent Non-Executive Chairman	7.2yrs	AU$188.28k	0.34% $ 16.2m
Chaitanya Divgi	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Rodney Hicks	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Neil Bander	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Mark Nelson	Independent Non-Executive Director	7.2yrs	AU$103.30k	1.08% $ 51.0m
Jann Skinner	Independent Non-Executive Director	6.4yrs	AU$111.56k	0.18% $ 8.4m
Jean-François Chatal	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Jason Lewis	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Klaus Kopka	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Samuel Samnick	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Richard Baum	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음

7.2yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: TLPP.F's board of directors are considered experienced (7.2 years average tenure).

Telix Pharmaceuticals 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Telix Pharmaceuticals Limited Announces Retirement of Andreas Kluge from the Board of Directors

Telix Pharmaceuticals Limited Announces Executive Changes

Telix Pharmaceuticals Limited Announces Leadership Changes

Telix Pharmaceuticals Limited Appoints Kevin Richardson as CEO, Telix Americas

Telix Pharmaceuticals Limited Announces Management Change

Telix Pharmaceuticals Limited Announces Board Changes

Recent updates

Telix Pharmaceuticals Limited Announces FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx Brain Cancer Imaging Agent

Telix Pharmaceuticals Limited Announces Retirement of Andreas Kluge from the Board of Directors

Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy

Health Canada Approves Label Expansion for Telix Pharmaceuticals Limited's Illuccix to Include Patient Selection for PSMA-Targeted Therapy

Telix Pharmaceuticals Initiates Phase II Trial for Tlx250-Cdx in Recurrent Clear Cell Renal Cell Carcinoma

Telix Pharmaceuticals Limited (ASX:TLX) agreed to acquire RLS (USA) Inc. from Rls Group Ltd for $250 million.

Telix Submits NDA for TLX101-Cdx (Pixclara®) Brain Cancer Imaging Agent

Telix Pharmaceuticals Limited Announces Expanded Access Program Opens in the U.S. for Tlx101-Cdx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent

Telix Pharmaceuticals Limited Updates Earnings Guidance for the Fiscal Year 2024

Telix Pharmaceuticals Limited has withdrawn its Follow-on Equity Offering in the amount of $201.79 million.

Telix Pharmaceuticals Limited Submits NDA for New Prostate Cancer Imaging Agent

Telix Pharmaceuticals Limited has filed an IPO in the amount of $100 million.

Telix Pharmaceuticals Limited has filed an IPO in the amount of $100 million.

Telix Pharmaceuticals Limited Reaffirms Revenue Guidance for the Year 2024

Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of ARTMS, INC.

Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of IsoTherapeutics Group, LLC for $8.1 million.

Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of IsoTherapeutics Group, LLC for $8.1 million.

Telix Pharmaceuticals Limited Announces First Patient Dosed in Italian Named Patient ( Early Access) Program for TLX250-CDx Telix's Kidney Cancer Imaging Agent

Telix Pharmaceuticals Limited (ASX:TLX) signed an agreement to acquire ARTMS, INC. for approximately $84 million.

Telix Pharmaceuticals Limited (ASX:TLX) entered into an agreement to acquire IsoTherapeutics Group, LLC for $13.6 million.

Telix Pharmaceuticals Limited Provides Earnings Guidance for Full Year Revenue 2024

Telix Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Feb 22, 2024

Telix Pharmaceuticals Limited Announces Executive Changes

Telix Pharmaceuticals Limited Submits Biologics License Application for TLX250-CDx (Zircaix) for Imaging of Kidney Cancer

Telix Pharmaceuticals Limited Announces First Patient Dosed in European Named Patient ( Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent

Telix Pharmaceuticals Limited Announces Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS

Telix Pharmaceuticals Limited (ASX:TLX) signed a non-binding term sheet to acquire QSAM Biosciences, Inc. (OTCPK:QSAM) for $33.1 million.

Telix Pharmaceuticals Limited (ASX:TLX) acquired Lightpoint Surgical Limited from Lightpoint Medical, Ltd AUD 51 million.

Telix Pharmaceuticals Limited Announces Positive Preliminary Results from the Phase I ProstACT SELECT Study of Its rADC Therapy Candidate TLX591

Telix Pharmaceuticals Limited Announces First Patients Dosed in Chinese Imaging Studies

Telix Pharmaceuticals Limited to Report Q3, 2023 Results on Oct 18, 2023

Telix Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 23, 2023

Telix Pharmaceuticals Limited to Report Q2, 2023 Results on Jul 19, 2023

Telix Pharmaceuticals Limited to Showcase ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline Developments at SNMMI

Telix Pharmaceuticals Limited (ASX:TLX) entered into an agreement to acquire Lightpoint Surgical Limited from Lightpoint Medical, Ltd for AUD 51 million.

Telix Pharmaceuticals Limited Announces First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion

Telix Pharmaceuticals Limited Announces Detailed Positive Results from its Completed Pivotal Phase III ZIRCON Trial

Telix Pharmaceuticals Limited to Report Q4, 2022 Results on Jan 18, 2023

Telix Pharmaceuticals Limited Announces ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances

Telix Pharmaceuticals Limited Announces Leadership Changes

Telix Pharmaceuticals Limited Announces Illuccix Kit for the Preparation of Gallium Ga 68 Gozetotide Injection

Telix Pharmaceuticals Limited Announces That First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy

Telix Pharmaceuticals Limited (ASX:TLX) agreed to acquire Optimal Tracers from Northern California PET Imaging Center.

Telix Pharmaceuticals Limited Announces Positive Topline Results from Overseas Phase III Clinical Trial Has Met Clinical Endpoints

Telix Pharmaceuticals Limited Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study

Telix Pharmaceuticals Limited Presents Preliminary Data on TLX250-CDx Indication Expansion at EANM

Telix Pharmaceuticals Limited to Report Q3, 2022 Results on Oct 20, 2022

Telix Pharmaceuticals Limited Announces Health Canada Approves Illuccix for Prostate Cancer Imaging

Telix Pharmaceuticals Limited Announces First Patient in New Zealand Dosed with Illuccix

Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate

Telix Pharmaceuticals Limited and GenesisCare announce First Patient Enroll in ProstACT TARGET Study

Telix Pharmaceuticals Limited Reports the Final Results from the IPAX-1 Ph I/II Study of TLX101 Therapy Iodo-Phenylalanine

Telix Pharmaceuticals Limited and Atonco S.A.S. Announce That the Final Patient Dosed in A Phase I Study of TLX250-CDx in Patients with Non-Muscle Invasive Bladder Cancer

Telix Pharmaceuticals Limited to Report First Half, 2022 Results on Aug 18, 2022

Telix Pharmaceuticals Limited Reports on APAC Regulatory Progress Prostate and Kidney Cancer Imaging

Telix Pharmaceuticals Limited Appoints Kevin Richardson as CEO, Telix Americas

Telix Pharmaceuticals Limited Announces Management Change

Telix Pharmaceuticals Limited Provides Reimbursement and Launch Updates

Telix Pharmaceuticals Limited Announces First Patient Has Been Dosed in the 'STARLITE 2' Phase II Study of the Company's Investigational Renal Cancer Therapy, TLX250 (177Lu-DOTA-girentuximab), At Memorial Sloan Kettering Cancer Center (MSK) in New York

Telix Pharmaceuticals Limited Announces First Patients Dosed with Illuccix® - Telix's Approved Prostate Cancer Imaging Agent

Telix Pharmaceuticals Limited Announces ProstACT TARGET Phase II Clinical Trial Update

Telix Pharmaceuticals Limited Announces Commercial Launch of Illuccix in the United States

Telix Pharmaceuticals Limited Announces Board Changes

Telix Pharmaceuticals Limited Completes ZIRCON Phase 3 Imaging Study Targets Enrolment

Telix Pharmaceuticals Limited, Annual General Meeting, May 18, 2022

Telix Pharmaceuticals Limited Appoints Darren Smith as Deputy Group Chief Financial Officer

Telix Pharmaceuticals Limited to Report Fiscal Year 2021 Results on Feb 24, 2022

Telix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 175.000002 million.

Telix Pharmaceuticals Limited Doses 1St Patient in Prostact Prostate Cancer Therapy Program